Grace Halsey

Adults with a cannabis-related acute care visit or hospitalization were at 23% and 72% greater risk of a new dementia diagnosis within 5 years, a new study finds.

Myths and fears about cancer screening may be keeping some of your patients from important tests. Always ask about misconceptions, and then offer the facts.

ACP 2025: Rachel Issaka, MD, MAS, reviewed data from a Kaiser Permanente program that narrowed racial and ethnic disparities in CRC screening compliance and related deaths.

Gestational diabetes and hypertensive disorders of pregnancy may be markers for rather than mediators of risk for future CVD, according to new research.

Following a Mediterranean-style diet and a prescribed regimen of physical activity was significantly protective of BMD, particularly at the lumbar level, over 3 years.

ACP 2025. A focused CRC prevention program begins with primary care where support and advocacy for regular screening begins, Issaka stressed.

The extended wear benefit is augmented by the G7 15 Day CGM system's superior evidence-based accuracy, with a MARD of 8.0%

Loss of lean muscle mass along with fat mass is a concerning side effect of the incretin-based antiobesity medications, making the new study results encouraging.

ACP 2025: Issaka, from the Fred Hutchinson Cancer Center, told internists that three-quarters of CRC deaths can be attributed to 3 types of screening failure.

Aprocitentan, when added to background therapy of at least 3 antihypertensive agents, led to clinically meaningful and sustained BP reduction in this preplanned subanalysis.

As the US measles outbreak tops 600 cases, Texas reported a second child's death in a young girl who was unvaccinated and had no underlying health conditions.

ACP 2025. The director of the UCSF Headache Center built an evidence-based framework for diagnosing and treating headache disorders seen in primary care.

In addition to support for phase 3 CLARITY AD findings, new evidence was presented supporting lecanemab safety and efficacy in ApoE ε4 carriers and non-carriers.

The investigational botanical zabalafin hydrogel has shown antipruritic, antibacterial, and anti-inflammatory properties, addressing the multifactorial nature of AD.

ACP 2025. Karol E Watson, MD, PhD, highlighted how traditional approaches to CV care have poorly addressed the unique presentations, risk factors, and pathophysiology of heart disease in women.

ACP 2025. Harvard gerontologist and preventive cardiologist Ariela Orkaby, MD, MPH, highlighted the many nuances required in the cardiovascular care of the aging population.

Black children were 2.4 to 4.1 times more likely to experience early-onset and persistent disease than White peers and much more likely to require urgent care for their AD.

Using the proprietary Roche Brainshuttle technology, trontinemab leads to deep, rapid amyloid plaque reduction with a favorable safety profile.

ACP 2025. Scripps Clinic's John M Kelso, MD, offered topline updates on all types of allergies including a step-by-step on how to "delabel" patients identified as penicillin-allergic.

Foluso A. Fakorede, MD, sketched a disturbing picture of recognition and management of PAD in the US, highlighting stark racial and ethnic disparities and making an urgent call to action.

The highest CRC mortality rates occur at the “intersection of race, place, and class," Rachel Issaka, MD, MAS, told internal medicine clinicians at the annual ACP meeting.

Dagogo-Jack reviewed alarming data on the damage prediabetes can inflict even decades before a diabetes diagnosis and offered guidance to the internal medicine audience.

ACP 2025. A quick look at 2 topics in dermatology rounded out a Multiple Small Feedings of the Mind session at the 2025 American College of Physicians annual meeting.

ACP 2025. Ruth Etzioni, PhD, discussed evidence-based approaches to screening for patients at average risk, start and stop criteria, MRI for follow-up screening, and other topics.

ACP 2025: Irl B Hirsch, MD, reviewed findings from 8 papers published in 2024 that he believes have made or will make a difference in the practice or understanding of the clinical area.

ACP 2025. Thomas Martens, MD, Gregg Simonson, PhD, and Libby Johnson, RDN, LD, CDCES explained the benefits of CGM, how to interpret data, and then adjust treatment accordingly.

Findings of the EXSTROM trial may help elucidate the mechanism by which low-dose colchicine prevents MI and stroke in adults with established CAD, experts suggest.

In treatment-resistant PTSD, TSND-201 was associated with statistically significant symptom improvement as early as day 10 in the phase 2 IMPACT-1 trial.

ACC.25. The results seen with the only oral GLP-1 mimetic reflect "a profound clinical impact" for adults at high risk for MACE who are averse to injectable therapy.

Lepodisiran at 400 mg maintained reductions of Lp(a), an inherited risk factor for cardiovascular disease, at ~90% at 1 year and ~75% at 1.5 years, Eli Lilly reported.